Quetiapine as Fumarate

Description

Introducing Quetiapine Fumarate Tablets by PharmAlliance International Labs Private Limited

Welcome to PharmAlliance International Labs, a premier provider of cutting-edge healthcare solutions. Our Quetiapine Fumarate Tablets represent a cornerstone in the treatment of various psychiatric disorders, underpinned by our unwavering commitment to patient well-being and satisfaction.

Drug Classification:

Quetiapine belongs to the class of medications known as atypical antipsychotics. Renowned for its efficacy, it is extensively utilized in the management of schizophrenia, bipolar disorder, and major depressive disorder, offering a ray of hope for patients grappling with these challenging conditions.

Formulations:

Quetiapine Fumarate Tablets:

Strength: Available in 25mg tablets (packed in 30’s) and 100mg tablets (packed in 30’s).

Product Form: Oral tablets for convenient administration.

Indications:

Quetiapine Fumarate Tablets are indicated for the following conditions:

• • Schizophrenia: Addressing the complex symptomatology of schizophrenia, characterized by hallucinations, delusions, and cognitive impairment, to restore stability and improve quality of life.
  • Bipolar Disorder: Managing manic episodes associated with bipolar I disorder, either as monotherapy or adjunctive therapy alongside lithium or divalproex, facilitating mood stabilization and preventing relapse.
  • Major Depressive Disorder (MDD): Serving as adjunctive therapy in adult patients with MDD who have not attained adequate response to antidepressant monotherapy, offering a multifaceted approach to treatment.

Usage:

Quetiapine Fumarate Tablets should be orally administered once or twice daily, with or without food, as prescribed by your healthcare provider. Dosage adjustments may be warranted based on individual response and tolerability, necessitating close collaboration with your healthcare professional to optimize treatment outcomes.

Dosage:

The recommended dosage regimen for Quetiapine Fumarate Tablets varies according to the targeted psychiatric disorder:

• • Schizophrenia: Initiate treatment at 25 mg twice daily, with gradual titration up to a maximum dose of 800mg daily, contingent upon clinical response and tolerability.
  • Bipolar Disorder: Commence therapy at 50 mg twice daily, with subsequent dose adjustments up to a maximum of 800mg per day, tailored to individual patient needs.
  • Major Depressive Disorder: Begin adjunctive treatment at 50 mg once daily, with incremental titration to a maximum daily dose of 300mg, facilitating augmentation of antidepressant therapy.

Pharmacokinetics:

Quetiapine exhibits favorable pharmacokinetic properties, characterized by rapid absorption following oral administration and peak plasma concentrations achieved within 1 to 2 hours. Extensive hepatic metabolism mediated by cytochrome P450 enzymes, notably CYP3A4 and CYP2D6, governs its elimination kinetics, with a half-life of approximately 6 to 7 hours, facilitating twice-daily dosing regimens.

Pharmacodynamics:

Quetiapine elicits its therapeutic effects through antagonism of dopamine D2 and serotonin 5-HT2A receptors within the central nervous system, engendering amelioration of psychotic symptoms and mood stabilization, thereby fostering enhanced psychosocial functioning and quality of life for affected individuals.

Side Effects:

While generally well-tolerated, Quetiapine Fumarate Tablets may engender certain adverse effects, including drowsiness, dizziness, dry mouth, constipation, and weight gain. Vigilance is warranted for the emergence of less common but potentially serious side effects such as orthostatic hypotension, tachycardia, or metabolic perturbations, necessitating prompt medical attention upon their occurrence.

Conclusion:

Place your trust in the efficacy and safety of Quetiapine Fumarate Tablets from PharmAlliance International Labs. Committed to pioneering advancements in mental health therapeutics, we stand at the forefront of innovation, dedicated to enriching the lives of individuals afflicted by psychiatric disorders worldwide. For further insights and guidance, we invite you to explore our website or engage with your healthcare provider.